Skip to content
Artwork for viroLOGICAL
Health & FitnessMedicineEducationScienceLife Sciences

viroLOGICAL

Florian Krammer & Podcastwerkstatt

Florian Krammer is a virologist and vaccine developer. In his podcast viroLOGICAL he will talk about viruses on a weekly basis – from historical pandemics to current developments.
A Podcastwerkstatt Original – produced between New York and Vienna.

Photocredit: Medical University of Vienna/feelimage

Play
  • 30 episodes
  • weekly
  • Avg 21 min
  • English
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • Wednesday · 19 min

    #40 – Hantaan Virus: From the Korean War to the Rats in Your City

    Recorded in Seoul, this episode is about Hantaan virus, the prototype hantavirus that gave the whole group its name. Florian Krammer explains how the disease first appeared during the Korean War in more than 3,000 soldiers, how virologist Ho-Wang Lee traced it to the striped field mouse in 1976 and isolated the virus two years later, and why the Hantan River is spelled with one A while the virus has two. The illness is known as Korean hemorrhagic fever with renal syndrome: after an incubation period of usually twelve to sixteen days come flu-like symptoms, a hypotensive phase, and a renal phase that often requires dialysis. The case fatality rate is around six percent today, with China reporting 9,000 to 12,000 cases a year and South Korea 400 to 600. The episode also covers Seoul virus, discovered by the same researcher in 1980: carried by Norway rats, it has spread worldwide with them and was found in about ten percent of rats sampled in New York City. Pet rats deserve particular attention after an outbreak across the US and Canada in 2016 and 2017. Overview of hemorrhagic fever with renal syndrome in Asia: https://pmc.ncbi.nlm.nih.gov/articles/PMC9966805/ Review about Seoulvirus in rats: https://pmc.ncbi.nlm.nih.gov/articles/PMC6669632/ Report about 2017 Seoulvirus outbreak in the US: https://pmc.ncbi.nlm.nih.gov/articles/PMC5794350/ +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.

    • Transcript
  • November 4 · 20 min

    #39 – Baculovirus: The Virus That Liquefies Its Victims

    For Halloween, this episode is about one of the scariest viruses around, at least if you’re an insect: the baculovirus. Florian Krammer explains how these large DNA viruses infect the caterpillars of moths and butterflies, change their behavior so they climb to the top of the plant, and then liquefy them so the virus spreads as widely as possible. Two forms of the virus make this possible: one that spreads within the insect and a highly stable form encased in protein crystals that can survive in the soil for years to decades. Because each baculovirus infects only one insect species, they have been used as targeted biopesticides since the 1940s, for example against the codling moth or the gypsy moth. Since the 1990s, they have also become a key biotechnology tool for producing proteins in insect cells, including for the HPV vaccine Cervarix, the flu vaccine Flublok and the Novavax COVID-19 vaccine. Recorded in Chile just before the International Hantavirus Conference. Baculovirus review article: https://www.ncbi.nlm.nih.gov/books/NBK543465/ Overview article about baculoviruses as pest control: https://biocommunication.org/en/insects360/insects-vs-plants/baculoviruses-a-natural-and-sustainable-solution-for-pest-control/ +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.

    • Transcript
  • October 28 · 17 min

    #38 – Shamonda Virus: What’s Behind the First Human Death in Europe

    Shamonda virus is a bunyavirus of the Simbu serogroup, closely related to Schmallenberg, Akabane and Oropouche virus. It was first identified in 1965 in Ibadan, Nigeria, and is known to infect cattle, sheep and goats, transmitted by biting midges. In summer 2026, it caused outbreaks in cattle in Switzerland, Germany, Austria and several other European countries, and two new variants were identified. In October, a person in France became the first known human fatality: a severely immunocompromised patient after a stem cell transplant, in whom metagenomic sequencing found the virus mainly in the brain. Florian Krammer explains why the risk for healthy people is very low, comparable to Usutu virus, and why serosurveys would help clarify how often humans are exposed. Paper describing the first (and fatal) human Shamonda virus case in France: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2026.31.42.2600883 Paper describing Shamonda virus EU1 in cattle in Germany: https://wwwnc.cdc.gov/eid/article/32/12/26-1496_article Paper describing Shamonda virus EU2 in cattle in Germany: https://pmc.ncbi.nlm.nih.gov/articles/PMC13633466/#sec2 +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.

    • Transcript
  • October 21 · 34 min

    #37 – Winter Is Coming: Update on Flu, COVID and RSV

    With the respiratory virus season starting, Florian Krammer gives an overview of what’s circulating and how to protect yourself. He explains why respiratory viruses spread more easily in the cold and how influenza plays ping pong between the northern and southern hemispheres. The focus is on the three viruses we have good countermeasures for. For SARS-CoV-2, the share of severe infections has been falling steadily since 2022, last year’s vaccines reached an effectiveness of 50 to 60 percent, and new options like the Spanish protein vaccine Bimervax and a combined COVID and flu mRNA vaccine are now available in Europe. Influenza causes 3 to 5 million severe cases and up to 650,000 deaths worldwide every year. An early H1N1 rise closely matches this year’s vaccine strain, and an mRNA flu vaccine has now been licensed in the US. For RSV, there are vaccines for adults over 60, maternal vaccination to protect newborns, and a monoclonal antibody for babies. Plus: why N95 masks and antivirals like Paxlovid, taken early, are useful additions. SARS-CoV-2 variant data from the US CDC: https://www.cdc.gov/covid/php/variants/variants-and-genomic-surveillance.html Influenza surveillance data from the US CDC: https://www.cdc.gov/fluview/ +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.

    • Transcript
  • October 14 · 20 min

    #36 – LCMV: Why Mice in Your Home Can Be a Risk

    Lymphocytic choriomeningitis virus (LCMV) is an arenavirus closely related to Lassa virus, but unlike Junin virus it isn’t limited to South America: it’s found worldwide in house mice. Florian Krammer explains how people get infected, mostly by inhaling dust from dried mouse urine, droppings or saliva, and less often through bites, contaminated food or infected pets like hamsters. Most infections go unnoticed, and studies from Croatia and Bratislava found antibodies in up to 40 percent of people. LCMV becomes dangerous for two groups: in organ transplant recipients it resembles a hemorrhagic fever with a fatality rate above 70 percent, and in pregnant women it can cause miscarriage or severe birth defects. There is no vaccine and no effective treatment. On the bright side, research with LCMV in mice revealed how T cells recognize infected cells, earning Rolf Zinkernagel and Peter Doherty the 1996 Nobel Prize. Recent review about LCMV: https://pmc.ncbi.nlm.nih.gov/articles/PMC8163193/ US CDC LCMV information: https://www.cdc.gov/lymphocytic-choriomeningitis/about/index.html +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.

    • Transcript
  • October 7 · 13 min

    #35 – Rustrela Virus: The Mystery of the Staggering Cats

    Since the 1970s, cats in Sweden, and later in and around Vienna, have been falling ill with a mysterious brain inflammation known as staggering disease. Affected cats develop fever, behavioral changes, a staggering gait and often paralysis of the hind legs, and most have to be euthanized. For decades Borna disease virus was the main suspect, but metagenomics finally solved the case: in 2023, rustrela virus, a close relative of rubella virus, was detected in 27 out of 29 affected cats from Sweden, Germany and Austria. Florian Krammer explains how cats catch the virus from the mice they hunt, why different mouse species carry it in Germany and Sweden, and why it has now also turned up in a mountain lion in Colorado. There is no vaccine and no treatment, and no human cases have been reported. He also introduces ViroKitty, a citizen science project in Vienna where cat owners can hand over their outdoor cats' prey for virus research. Video of mountain lion in Colorado with staggering disease/rustrelavirus infection: https://www.youtube.com/watch?v=KtofjO4Tfds Information about rustrelavirus and staggering disease: https://www.abcdcatsvets.org/guideline-for-staggering-disease/ Project ViroKitty: https://soap.lbg.ac.at/virokitty-how-your-cat-can-become-a-virologist/ +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.

    • Transcript
  • September 30 · 15 min

    #34 – Junin Virus: A 30 Percent Fatality Rate, but There's a Vaccine

    Junin virus causes Argentine hemorrhagic fever, a disease with a case fatality rate of 20 to 30 percent. Florian Krammer explains why these New World arenaviruses are named after sand (they package host cell ribosomes that look like grains of sand under the electron microscope) and what makes their spike protein unusual: the signal peptide stays part of the glycoprotein complex, something found nowhere else in biology. The virus is carried by field mice, mainly the dryland vesper mouse, and people usually get infected by inhaling dust from dried urine and feces. That's why it mostly affects men working in agriculture, with over 90 percent of the 300 to 500 annual cases occurring in rural areas. Unlike most hemorrhagic fevers, this one has countermeasures: the live attenuated vaccine Candid One with 95 percent efficacy, and convalescent plasma that cuts fatality to one or two percent but causes late neurological symptoms in about 8 to 10 percent of patients. Florian Krammer's own lab is about to publish monoclonal antibodies that could replace plasma therapy. Information about Junin virus and Argentine hemorrhagic fever from the UK Health Security Agency: https://www.gov.uk/guidance/argentine-haemorrhagic-fever-origins-reservoirs-transmission-and-guidelines New paper about Junin virus monoclonal antibodies that could be used for treatment: https://journals.asm.org/doi/10.1128/mbio.00214-26 +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.

    • Transcript
  • September 23 · 13 min

    #33 – HMPV: The Common Respiratory Virus Nobody Knows

    Human metapneumovirus (HMPV) is one of the most common respiratory viruses there is, yet few people have heard of it. Florian Krammer explains why this relative of RSV is the second most common cause of respiratory illness in children under five and is behind 8 to 15 percent of pneumonia cases in that age group. Virtually every child has been infected by age five, but immunity doesn't last, so reinfections happen throughout life. The highest risk falls on premature babies, infants between six and twelve months, adults over 65, and people with COPD, asthma or weakened immune systems. HMPV was only discovered in 2001 in Rotterdam but has likely circulated in humans for around 200 years after jumping from birds. Unlike RSV, there are no vaccines or antibody treatments yet, though combination vaccines are in clinical trials. Human metapneumovirus information from the CDC: https://www.cdc.gov/human-metapneumovirus/about/index.html Human metapneumovirus information from the WHO: https://www.who.int/news-room/questions-and-answers/item/human-metapneumovirus-(hmpv)-infection +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.

    • Transcript
  • September 16 · 31 min

    #32 – Spanish Flu: Why It Also Killed the Young and Healthy

    The 1918 Spanish flu was the deadliest influenza pandemic on record: between 20 and 100 million people died, from a world population of just 1.8 billion at the time. Florian Krammer explains why this H1N1 virus, with a case fatality rate of two to three percent, was so dangerous, where the misleading name comes from (Spain was neutral and had a free press when warring countries did not) and why mortality peaked among 20 to 40 year olds in a distinctive W-shaped curve. He also lays out his own hypothesis: seasonal influenza may have vanished entirely between 1891 and 1918, leaving a whole generation with no immunity at all. The episode covers cytokine storms, anti-mask leagues, famous victims including Gustav Klimt and Egon Schiele, and the reconstruction of the virus from formalin-fixed pathology slides and a body exhumed from Alaskan permafrost. It closes with 2009, when a descendant of the 1918 virus jumped back out of pigs into people. Link to John Barry’s book ‘The Great Influenza’: https://en.wikipedia.org/wiki/The_Great_Influenza Review article about the 1918 H1N1 pandemic by Jeff Taubenberger and David Morens: https://pmc.ncbi.nlm.nih.gov/articles/PMC7528857/ +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.

    • Transcript
  • September 9 · 16 min

    #31 – Canine Distemper: The Dog Virus That Threatens Whole Species

    Canine distemper virus is a paramyxovirus and a close relative of measles virus. Florian Krammer explains why the disease is so dangerous for unvaccinated dogs: in puppies between three and six months the case fatality rate is around 80 percent, and roughly 50 percent in adult dogs with no immunity. Once the virus reaches the central nervous system, the outcome is usually fatal. What makes it especially troubling is its host range: wolves, foxes, red pandas, lions, tigers, elephants, bears, raccoons and badgers can all be infected, which turns distemper into a conservation problem. An outbreak in the Serengeti killed around 20 percent of the lion population in 1993, and the related phocine distemper virus killed roughly 18,000 harbour seals in the North Sea in 1998. Humans don't get sick, probably in part because of cross-protection from measles immunity. Good vaccines have existed since the 1960s but need regular boosting. General information about canine distemper virus: https://www.avma.org/resources-tools/pet-owners/petcare/canine-distemper +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.

    • Transcript
  • September 2 · 15 min

    #30 – Dabie Bandavirus: The Tick Virus From Asia

    Recorded in Sapporo, this episode is about a virus causing severe disease across Asia: SFTS virus, officially named Dabie bandavirus. It spreads mainly through the Asian longhorned tick, and in rare cases directly between people via blood and bodily fluids. Florian Krammer explains why the fatality rate of 10 to 30 percent is so alarmingly high, why it's almost exclusively older people in rural parts of China, Japan and South Korea who fall ill, and what lies behind the unwieldy name: severe fever with a dramatic drop in blood platelets. There's also a fascinating American relative, Heartland virus, discovered in Missouri in 2009 and now detected in more than a dozen US states. No vaccine exists and the available drugs barely help, which leaves proper tick protection as the only real defence. Meta-analysis of SFTSV epidemiology: https://pmc.ncbi.nlm.nih.gov/articles/PMC11261768/ SFTSV review paper: https://pmc.ncbi.nlm.nih.gov/articles/PMC12325320/ Information about Heartland virus from the US CDC: https://www.cdc.gov/heartland-virus/hcp/clinical-diagnosis/index.html Retrospective analysis of the 1996 cluster in Jiangsu: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006603 +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.

    • Transcript
  • August 26 · 21 min

    #29 – Cytomegalovirus: The Quiet Lifelong Passenger

    This time it's a herpes virus that almost all of us carry: human cytomegalovirus (CMV). Florian Krammer explains why this large DNA virus with over 200 proteins is so hard to pin down, how it deposits its genome as an episome inside immune cells and stays hidden there for decades. In healthy people the infection usually goes unnoticed, but in transplant patients or pregnant women it can cause serious harm, from organ inflammation to birth defects. The episode also covers reactivation under stress (including astronauts on the ISS and long COVID), associations with cancer, Alzheimer's and immune ageing, and why decades of vaccine development have so far come up short. US CDC information about CMV: https://www.cdc.gov/cytomegalovirus/about/index.html Review article about CMV vaccines (slightly outdated, January 2025): https://pmc.ncbi.nlm.nih.gov/articles/PMC11684802/ Nature article about CMV (and herpesvirus) reactivation in COVID-19 and Long COVID patients: https://pubmed.ncbi.nlm.nih.gov/42557313/ +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.

    • Transcript
  • August 19 · 24 min

    #28 – Mumps: Why the Vaccine Is Faltering and Cases Are Rising

    This time it's a virus that has circulated in humans for millennia: mumps virus. Florian Krammer explains why this paramyxovirus is related to measles and the dangerous Nipah virus, how the infection unfolds, and why it's usually mild but can cause serious complications including inflammation of the testicles, brain, or pancreas. The episode traces the history from Hippocrates to its identification as a viral disease in 1934, along with the story of how Merck researcher Maurice Hilleman developed the vaccine still used today from a swab of his own sick daughter. The MMR vaccine brought mumps close to elimination, but vaccine hesitancy, waning immunity, and viral evolution are pushing case numbers back up worldwide. The Maurice Hilleman biography mentioned in this episode: https://nihlibrary.overdrive.com/media/134323 Picture of a child with the typical mumps swelling: https://en.wikipedia.org/wiki/Mumps#/media/File:Mumps_PHIL_130_lores.jpg US CDC mumps information page: https://www.cdc.gov/mumps/hcp/clinical-overview/index.html +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.

    • Transcript
  • August 12 · 17 min

    #27 – Summer Update: What's Happening in Virology Right Now

    A summer update with four current stories from the world of virology. First stop is Switzerland, where thousands of cows fell ill from a newly discovered orthobunyavirus of the Simbu group, closely related to Schmallenberg virus but with little risk to humans. Next comes a sobering update on the Bundibugyo Ebola outbreak in the Democratic Republic of Congo, which with over 4,000 cases is now the second-largest in history, though first clinical trials of treatments and vaccines have begun. There's also a new and probably harmless Andes virus case in a traveller in Europe, unrelated to the earlier cruise ship outbreak. And finally the most controversial item: researchers from Stanford and the Arc Institute used artificial intelligence to generate working viruses (harmless bacteriophages), sparking a major debate about biosecurity and the lack of regulation. Informations about the new orthobunyavirus in Switzerland: https://www.ivi.admin.ch/en/neues-orthobunyavirus-der-simbu-serogruppe-bei-rindern-entdeckte Bundibugyo ebola outbreak update: https://www.cdc.gov/ebola/situation-summary/index.html Information about the new Andesvirus case in France/Spain: https://www.santepubliquefrance.fr/en/news/andes-hantavirus-implementation-epidemiological-investigations-and-contact-tracing-following Science article about the AI bacteriophage: https://www.science.org/doi/10.1126/science.aec2657 +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.

    • Transcript
  • August 5 · 18 min

    #26 – Travel Viruses: West Nile Fever – Now in Central Europe Too

    The final part of the summer series on vacation viruses is one you can catch without going anywhere: West Nile virus. Florian Krammer explains why this flavivirus is closely related to Japanese and St. Louis encephalitis virus, how it mysteriously showed up in New York in 1999 - most likely via mosquitoes on a container ship and spread across the entire US within a few years. It has since reached Austria too, mainly in the east (Vienna, Lower Austria, Burgenland). Birds are the real reservoir, while humans and horses are dead-end hosts. The good news: 80% of infections are symptomless. The bad news: in rare cases the virus invades the nervous system, and then the fatality rate is around 10%. A striking detail: the very CCR5 mutation that protects against HIV raises the risk of severe West Nile disease. There's no vaccine for humans, only mosquito protection helps. West Nile virus information from the US CDC: https://www.cdc.gov/west-nile-virus/index.html West Nile virus information from the WHO: https://www.who.int/news-room/fact-sheets/detail/west-nile-virus +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.

    • Transcript
  • July 29 · 13 min

    #25 – Travel Viruses: Oropouche Virus From the Amazon

    Part three of the summer series on viruses you can pick up on vacation. After Italy and Scandinavia, it's off to the tropics. Oropouche virus causes Oropouche fever and is spread not by mosquitoes but mainly by tiny midges — the same bloodsuckers that transmit bluetongue disease. Florian Krammer explains why it's related to more dangerous viruses like Crimean-Congo hemorrhagic fever and Rift Valley fever virus, how it moves between a rainforest cycle (involving sloths, monkeys and birds) and a more troubling urban human-to-human cycle, and why the symptoms often come in two waves — they fade, then return after seven to ten days. Most infections are mild, but in rare cases it can cause meningitis, Guillain-Barré syndrome, or serious harm to an unborn child. There's no vaccine and no treatment — avoiding bites is the only protection. Oropouche virus review: https://pmc.ncbi.nlm.nih.gov/articles/PMC11945866/ US CDC Oropouche overview: https://www.cdc.gov/oropouche/hcp/clinical-overview/index.html +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.

    • Transcript
  • July 22 · 11 min

    #24 – Travel Viruses: Scandinavia, Mosquitoes and Sindbis Virus

    Part two of the summer series on viruses you might pick up on vacation — this time heading north. Sindbis virus is transmitted by ordinary Culex mosquitoes and causes a disease known variously as Pogosta disease, Ockelbo disease, or Karelian fever. Florian Krammer explains why it's closely related to chikungunya (you could call it the chikungunya of the north), how migratory birds spread it across Eurasia and Africa, and why most infections go unnoticed — there are 20 to 40 asymptomatic cases for every symptomatic one. Those who do get sick often develop stubborn arthralgia in the wrists, ankles and fingers that can last six to eight months, sometimes years. Curiously, larger outbreaks in Finland seem to occur roughly every seven years — the last one in 2021. No vaccine, no antiviral treatment: mosquito repellent and long sleeves are the only defence. Nice review about Sindbis virus: https://pmc.ncbi.nlm.nih.gov/articles/PMC12758272/ ECDC fact sheet about Sindbis virus: https://www.ecdc.europa.eu/en/sindbis-fever/facts +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.

    • Transcript
  • July 15 · 10 min

    #23 – Travel Viruses: Pappataci Fever and Toscana Virus

    The first of a short series on viruses you might encounter while travelling: Pappataci fever is transmitted by sandflies and caused by viruses like Toscana virus, Naples virus, and Sicilian sandfly fever virus. Florian Krammer explains where the Italian name comes from, why these tiny 3-millimetre flies are poor fliers and therefore stay close to the ground, and why up to 25% of people in affected regions carry antibodies without ever having felt sick. Most infections are mild, but Toscana virus is neurotropic and can, in rare cases, cause meningitis or encephalitis. There's no vaccine and no treatment — insect repellent and long trousers are your only defence. Link to Italian study showing an increase in neuro-invasive Toscana virus cases in 2022/2023: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2025.30.2.2400203 ECDC information about Toscana virus (a little outdared): https://www.ecdc.europa.eu/en/toscana-virus-infection +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.

    • Transcript
  • July 8 · 23 min

    #22 – Marburg Virus: Why This Infection Is So Dangerous

    In this episode of viroLOGICAL, Florian Krammer explains the Marburg virus, a filovirus closely related to Ebola that causes severe hemorrhagic fever. He discusses how the virus is structured, how it enters cells, how it is transmitted from animals and between humans, and why infection is associated with very high mortality. The episode also covers the typical course of the disease, historical outbreaks from Europe to Africa, the role of bats as a natural reservoir, and why—despite its severity—Marburg virus is unlikely to cause a pandemic due to limited human-to-human transmission. Washington Post article about bats and Marburg virus in caves in Uganda: https://www.washingtonpost.com/news/national/wp/2018/12/13/feature/these-bats-carry-the-lethal-marburg-virus-and-scientists-are-tracking-them-to-try-to-stop-its-spread/ Article about a US tourist who got infected in one of the bat caves: https://www.cidrap.umn.edu/ebola/american-traveler-survived-marburg-fever-cdc-says Nature article about animals feeding on Marburg virus infected bats: https://www.nature.com/articles/d44148-025-00221-2 US CDC information about Marburg virus: https://www.cdc.gov/marburg/about/index.html Video of bats and snakes in a cave in Uganda: https://www.youtube.com/watch?v=iw_sHKXtBZs +++++ Support viroLOGICAL on Steady: You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.

    • Transcript
  • July 1 · 16 min

    #21 – Cancer Vaccines: How the Immune System Learns to Recognize Tumors

    This time it's not about a virus, but about one of the most exciting developments in modern medicine: therapeutic cancer vaccines based on mRNA. Florian Krammer explains the basic principle — how a patient's tumor is sequenced, how the mutated genes (so-called neoantigens) are turned into a personalized vaccine, and how that vaccine trains the immune system to recognize and destroy cancer cells. Two recent trials show just how promising the approach is: a BioNTech vaccine against the notoriously aggressive pancreatic cancer, and a Moderna/Merck vaccine against melanoma, which now has five-year data. The vaccines aren't on the market yet and remain expensive to produce, but the direction is clear. Links to the original and follow up publications for the pancreatic cancer vaccine: https://www.nature.com/articles/s41586-023-06063-y https://www.nature.com/articles/s41586-024-08508-4 Links to the original and follow up publications for the melanoma vaccine (unfortunately partially behind paywalls): https://pubmed.ncbi.nlm.nih.gov/38246194/ https://pubmed.ncbi.nlm.nih.gov/42223134/ +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.

    • Transcript
Showing 1–20 of 30 episodes